NBSE * Stock Overview
A preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NeuBase Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.00 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.83 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| NBSE * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 0% | 0% | 0% |
Return vs Industry: NBSE * exceeded the MX Biotechs industry which returned -6% over the past year.
Return vs Market: NBSE * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| NBSE * volatility | |
|---|---|
| NBSE * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: NBSE * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NBSE *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 37 | Dietrich Stephan | www.neubasetherapeutics.com |
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington’s disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene.
NeuBase Therapeutics, Inc. Fundamentals Summary
| NBSE * fundamental statistics | |
|---|---|
| Market cap | Mex$109.21m |
| Earnings (TTM) | -Mex$424.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs NBSE * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBSE * income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.59m |
| Earnings | -US$24.59m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NBSE * perform over the long term?
See historical performance and comparison